Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Replimune Group Inc
Healthcare
P/NCAV
1.02x
Ticker
REPL
Exchange
NASDAQ
Country
United States
Close
6.42 $
Mkt Cap
373.7M $
EV
346.7M $
NCAV Burn Rate
32.0%
Current Ratio
12.4
Debt/Equity
0.17
EV/REV
N/Ax
EV/EBIT
-2.0x
EV/FCF
-2.8x
Dilution
11.2% p.A
Total Net Income
-484.1M $
Cheapness
98.0%
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company-s lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company-s pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average